Research programme: Duchenne muscular dystrophy gene therapy - Solid GT

Drug Profile

Research programme: Duchenne muscular dystrophy gene therapy - Solid GT

Alternative Names: SGT-001

Latest Information Update: 22 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Missouri-Columbia
  • Developer Solid GT; University of Missouri-Columbia
  • Class Gene therapies
  • Mechanism of Action Dystrophin expression stimulants; Gene expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 11 May 2017 Pharmacokinetics, immunogenicity and pharmacodynamics data from preclinical studies in Duchenne muscular dystrophy released by Solid Biosciences
  • 24 Oct 2016 SGT 001 receives Orphan Drug status for Duchenne muscular dystrophy in European Union
  • 24 Oct 2016 SGT 001 receives Orphan Drug status for Duchenne muscular dystrophy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top